Antoni van Leeuwenhoek

What Antoni van Leeuwenhoek does

Antoni van Leeuwenhoek (AVL), operating as Stichting Het Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL), is a Comprehensive Cancer Center founded in 1913 and headquartered in Amsterdam. It is the only dedicated cancer hospital in the Netherlands, combining specialized oncology care with integrated scientific research under a single nonprofit foundation structure. The institution serves cancer patients across all major tumor types via GP and specialist referrals, offering surgery, chemotherapy, radiotherapy, immunotherapy, targeted therapy, clinical trials, second opinions (including international), and survivorship care, with 9.0/10 patient satisfaction on Zorgkaart Nederland and 0% 30-day mortality for testicular cancer patients in a recent cohort.

Core technical and operational assets include an MR Linac system for image-guided adaptive radiotherapy, an in-house pharmacy laboratory with OECD GLP certification (inspected biennially since 1999) and GMP-compliant quality control, Therapeutic Drug Monitoring (TDM) services for oral oncolytics, custom chemotherapy and immunotherapy preparation in IGJ-certified rooms, an early diagnostics center, a Center for Quality of Life, and a dedicated bioanalytical laboratory offering services to third-party institutions. Digital patient-facing products comprise the MijnAVL portal (DigiD-secured), the BeterDichtbij messaging app, and Microsoft Teams-based video consultations. AI capabilities are deployed for MRI breast cancer detection, adaptive radiotherapy, and a treatment-effect measurement model launched in June 2026.

The business model operates within the Dutch mandatory basic health insurance system, with reimbursement contracts across all Dutch insurers and a €385 annual patient own-risk fee. Additional revenue streams include pharmacy laboratory services to external healthcare institutions and research sponsors, donations through the AVL Foundation (ANBI-recognized), and research grants from bodies including KWF. Distribution is direct via the Amsterdam main facility, a radiotherapy branch in Hoofddorp, and a national referral network, with cross-border second opinion services extending international reach.

Name

Antoni van Leeuwenhoek

Legal name

Stichting Het Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis

Website

https://avl.nl

Company type

Private

Founded year

1913

Operating status

Operating

Headcount range

1,001–5,000 employees

Ownership category

akta.pro rank

Product category

Cancer Hospital Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Offices of Physicians (62111), Medical and Diagnostic Laboratories (62151)

SIC

Services-Hospitals (8060), Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Medical Laboratories (8071)

akta.pro primary industry

Oncology Telemedicine Platforms (HLALAGAH)

akta.pro secondary industry

Virtual Specialty Care Platforms (tele-stroke, tele-ICU, tele-derm, tele-cardiology) (HLALABAD)

Keywords

• Cancer hospital services
• Oncology treatment
• Clinical cancer research
• Radiotherapy services
• Cancer diagnostics

Headquarters

HQ city

Amsterdam

HQ country

Netherlands

HQ region

Europe

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Healthcare Services Reimbursement: Hospital provides cancer treatment services covered under Dutch basic health insurance. Financial agreements with all insurance providers in Netherlands for cancer treatment coverage. Treatments covered under mandatory basic insurance with additional coverage options for certain treatments.
2. Patient Co-payments and Own Risk: Patients pay mandatory own risk fee (first 385 euros per calendar year). Additional costs for treatments not covered by basic insurance may require patient payment or fall under supplementary insurance.
3. Donations and Foundation Support: AVL Foundation accepts donations to support cancer research. Tax-deductible donations under ANBI status. Multiple giving options including one-time donations, becoming a friend, sporting actions, birthday actions, corporate contributions, and legacy bequests.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

Core offering

Antoni van Leeuwenhoek (AVL) is a Comprehensive Cancer Center that delivers specialized oncology care combining surgery, chemotherapy, radiotherapy, immunotherapy, targeted therapy, and clinical trials with integrated cancer research, diagnostics, survivorship support, and a hospital pharmacy with bioanalytical laboratory services. Patients access services through GP or specialist referrals at the Amsterdam main hospital, the Hoofddorp radiotherapy branch, and via digital channels including MijnAVL patient portal, BeterDichtbij app, and video consultations.

Product overview

Antoni van Leeuwenhoek (AVL) / Netherlands Cancer Institute (NKI) is a Comprehensive Cancer Center combining specialized cancer care with groundbreaking research since 1913. The institution offers a unified portfolio of patient-facing digital services alongside clinical care programs. Core digital products include MijnAVL (patient portal for appointments, medical records, and questionnaires), BeterDichtbij (mobile messaging app for secure patient-provider communication), and Video Consultation (using Microsoft Teams for remote appointments). Clinical centers include the Center for Early Diagnostics for rapid cancer detection, the Center for Quality of Life for supportive care and survivorship research, the Hospital Pharmacy with oncotheek for oral cancer medications and a specialized Pharmacy Laboratory supporting clinical studies with TDM services, and the Radiotherapy Department with MR Linac technology for image-guided therapy. The institution also operates a radiotherapy branch in Hoofddorp and a patient information center.

Differentiator

Problem solved

Functional benefit

Products and services

• MijnAVL Patient Portal Patient portal providing access to appointments, parts of medical records, patient education, and digital questionnaires for cancer patients of the Netherlands Cancer Institute. Patients log in with DigiD and SMS verification.
• BeterDichtbij Secure Messaging Mobile app for secure, low-threshold digital communication between cancer patients and their healthcare providers. Patients can ask non-urgent questions about appointments or treatment and receive responses within two working days.
• Video Consultation (Videoconsult) Video appointment service using Microsoft Teams that allows cancer patients to consult with care providers remotely via laptop, mobile phone, or tablet without traveling to the hospital. Remote consultations may be declared to the health insurer and count toward patient own risk.
• Center for Early Diagnostics (Centrum voor Vroegdiagnostiek) Specialized center for early cancer detection using the latest methods, techniques, and equipment, located in a building opposite the main entrance. Aims to provide clear diagnoses as quickly as possible for patients with suspected cancer.
• Center for Quality of Life (Centrum voor Kwaliteit van Leven) Center dedicated to alleviating physical, mental, and social issues that cancer patients may experience during and after treatment. Offers supportive care services and conducts clinical trials on quality-of-life interventions for cancer survivors.
• Hospital Pharmacy (Apotheek) with Oncotheek Hospital pharmacy providing medications including oral cancer drugs (oncotheek), custom-made medications such as chemotherapy and immunotherapy in specialized preparation rooms with IGJ certification, and pharmaceutical research support through the Pharmacy Laboratory including Therapeutic Drug Monitoring for oral oncolytics.
• Radiotherapy Department and Branch in Hoofddorp Radiotherapy services delivered at the main Amsterdam location and a branch in Hoofddorp near Spaarne Gasthuis, providing radiation treatment for cancer patients closer to their homes in the North Holland region.
• MR Linac (Image-Guided Adaptive Radiotherapy) Advanced radiotherapy system combining MRI imaging with linear accelerator radiation delivery for precise, adaptive cancer treatment. Enables real-time image guidance during radiation sessions for improved accuracy.
• Second Opinion Service Expert second opinion service for cancer diagnosis or treatment plans. Specialists assess medical data and provide consultation within approximately 5 working days. International patients can request second opinions with documents translated to Dutch or English. If insurance does not cover, an advance payment of €500 is required.
• Clinical Trials (Klinische Studies) Clinical trials program providing cancer patients access to experimental and investigational treatments, integrated with the institute's research mission and participation in European consortia including Cancer Core Europe and Oncode Institute.
• Pharmacy Laboratory (Bioanalytical and Quality Control Services) Pharmacy laboratory providing GLP-compliant bioanalytical testing (OECD GLP inspected every 2 years since 1999) and GMP-compliant pharmaceutical quality control services. Includes Therapeutic Drug Monitoring for oral oncolytics, bioanalysis of clinical study samples, advanced analytical instrumentation (triple quadrupole MS, orbitrap MS, U(H)PLC, GC, chiral separations, Dried Blood Spots), and customized medication preparation including chemotherapy and immunotherapy. Services provided to internal clinical studies and external third-party healthcare institutions.

Quantifiable outcome

• 9.0 patient satisfaction rating on Zorgkaart Nederland
• +4 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration6 records

AI capability6 records

Feature8 records

Partnerships

Twelve partnerships are on record, tiered core and minor.

• KWF Cancer SocietycoreStrategic or Co-development PartnerLong-standing partnership with Dutch cancer research funding organization. KWF provides financial support for cancer research projects and programs at the institute.
• EU-LIFEcoreStrategic or Co-development PartnerEuropean alliance of leading life science research institutes. Facilitates collaboration, knowledge exchange, and research cooperation among European top research institutions.
• Cancer Core EuropecoreStrategic or Co-development PartnerEuropean consortium of leading cancer centers working together to accelerate development and implementation of precision medicine for cancer patients through shared research and clinical trials.
• Center for Personalised Cancer Treatment (CPCT)coreStrategic or Co-development PartnerDutch consortium focused on personalized cancer treatment approaches, utilizing molecular profiling and genetic data to guide treatment selection.
• Oncode InstitutecoreStrategic or Co-development PartnerDutch cancer research institute combining fundamental and translational research to develop new cancer treatments and diagnostic tools.
• Organization of European Cancer Institutes (OECI)coreStrategic or Co-development PartnerPan-European organization connecting cancer institutes across Europe to promote collaboration, share best practices, and advance cancer care standards.
• Dutch Federation of Cancer Patient Associations (NFK)coreStrategic or Co-development PartnerCollaboration with patient advocacy organizations representing Dutch cancer patients, ensuring patient perspectives inform care improvements and research priorities.
• Amsterdam UMCcoreStrategic or Co-development PartnerCollaboration with Amsterdam University Medical Center and other universities and medical centers for research cooperation, knowledge sharing, and in various disease-specific networks.
• Prostate Cancer Network NetherlandsminorStrategic or Co-development PartnerCollaboration within specialized cancer network for prostate cancer care coordination, guideline development, and shared best practices.
• CGOA (Gynecological Cancer Network)minorStrategic or Co-development PartnerCollaboration within Dutch network for gynecological cancer care, focusing on cervical, ovarian, uterine, and vaginal cancers.
• Third-Party Healthcare InstitutionsminorStrategic or Co-development PartnerPharmacy laboratory services provided to external hospitals and research institutions beyond the main AVL facility.
• Dutch Breast Cancer Society (BVN)minorStrategic or Co-development PartnerPatient information sessions on breast prosthetics offered monthly at the institute, providing independent advice for women who underwent breast reconstructive surgery.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Memorial Sloan Kettering Cancer Center: Global benchmark for dedicated cancer hospitals with embedded research. Comparable in model (single-disease specialist hospital + research institute), though materially larger and operating in the US private insurance system.

Others

• KWF Dutch Cancer Society: Primary Dutch cancer research funder and long-standing AVL partner. Adjacent: not a provider but the dominant funder shaping AVL's research priorities and a key ecosystem participant.
• Oncode Institute: Dutch cancer research alliance that AVL is partnered with. Adjacent peer: not a hospital but a strategic research collaborator shaping the Dutch oncology research ecosystem in which AVL operates.

Direct peers

• European Institute of Oncology (IEO): Milan-based dedicated cancer hospital and research center founded by Umberto Veronesi. Directly comparable as a specialty oncology-only institution combining surgery, medical oncology, radiotherapy, and translational research.
• Vall d'Hebron Institute of Oncology (VHIO): Barcelona-based oncology research and translational care institute embedded in a university hospital. Comparable in combining clinical trials, molecular profiling, and specialized cancer care, and is also a Cancer Core Europe member like AVL.
• The Royal Marsden NHS Foundation Trust: UK's dedicated cancer hospital, jointly operating with the Institute of Cancer Research. Directly comparable to AVL as a single-disease specialist hospital pairing clinical oncology with translational research and strong international second-opinion flows.
• Gustave Roussy: Largest Comprehensive Cancer Center in Europe, combining oncology care with research in the Paris region. Closest functional peer to AVL: dedicated cancer-only institution with embedded research institute, multidisciplinary tumor care, and international trial activity.

Regional players

• Oslo University Hospital (Radiumhospitalet): Norway's principal cancer hospital within Oslo University Hospital, focused on radiotherapy and oncology. Comparable in offering dedicated specialty cancer care tied to a Nordic public reimbursement system.
• Karolinska University Hospital: Swedish university hospital hosting one of Europe's leading cancer centers. Comparable in offering advanced oncology care, research integration, and clinical trials within a Northern European publicly-funded system.
• Charité – Universitätsmedizin Berlin: Germany's largest university hospital with a Comprehensive Cancer Center. Comparable as a public-sector research hospital delivering complex oncology care, though broader than AVL's single-disease focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/watch?v=Ys8MkqlVWmM
• Facebookfacebook.com/HetAntoniVanLeeuwenhoek
• LinkedInlinkedin.com/company/antoni-van-leeuwenhoek

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Antoni van Leeuwenhoek